A case of acute interstitial pneumonia which developed during the interferon and ribavirin treatment for chronic hepatitis C Source: Eur Respir J 2005; 26: Suppl. 49, 84s Year: 2005
Successful hepatitis B treatment with lamivudine and interferon-alpha in a patient with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 617s Year: 2004
Advantages of intravenous chemotherapy for tuberculosis patients with viral hepatitis Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Fatal interstitial pneumonitis in a patient treated with pegylated interferon alpha-2b and ribavirin for hepatitis C infection Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003
Hepatotoxicity of antituberculosis chemotherapy in patients with liver cirrhosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Sarcoidosis associated with interferon-α therapy for chronic hepatitis C Source: Eur Respir J 2006; 28: Suppl. 50, 541s Year: 2006
Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006
Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015
Sarcoidosis caused by interferon therapy: case report Source: Eur Respir J 2003; 22: Suppl. 45, 233s Year: 2003
Rifamycin induced leukocytoclastic vasculitis. A rare side-effect of anti-tuberculous chemotherapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007
Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis Source: Eur Respir J 2006; 28: Suppl. 50, 13s Year: 2006
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease Source: Eur Respir J 2005; 25: 570-573 Year: 2005
Response of pulmonary tuberculoma to anti-tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 521s Year: 2003
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007